Stockscreener 앱 받기
28.19
1.02%
-0.29
시장 영업 전:
28.43
0.24
+0.85%
전일 마감가:
$28.48
열려 있는:
$28.67
하루 거래량:
880.69K
Relative Volume:
0.78
시가총액:
$1.65B
수익:
$32.87M
순이익/손실:
$674.31M
주가수익비율:
2.4815
EPS:
11.36
순현금흐름:
$-330.11M
1주 성능:
-5.91%
1개월 성능:
+1.77%
6개월 성능:
-21.98%
1년 성능:
-15.57%
1일 변동 폭
$28.13
$29.37
1주일 범위
$27.71
$30.52
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
28.19 | 1.67B | 32.87M | 674.31M | -330.11M | 11.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors o - GuruFocus
How The Agios Pharmaceuticals (AGIO) Story Is Shifting After Aqvesme Approval And New Targets - Yahoo Finance
Levi & Korsinsky Reminds Agios Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities LawsAGIO (2026-03-04) - Seeking Alpha
Agios Pharmaceuticals, Inc. $AGIO Shares Sold by TD Asset Management Inc - MarketBeat
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact The Gross Law Firm Regarding Potential Securities Law ViolationsAGIO - StreetInsider
Agios (AGIO) CMO logs tax-driven share sales and major new equity awards - Stock Titan
Agios (NASDAQ: AGIO) CEO Brian Goff receives large equity grants, sells shares for tax withholding - Stock Titan
AGIOS (AGIO) legal chief gains RSUs, options and sells shares for taxes - Stock Titan
Agios Pharmaceuticals (AGIO) CFO equity grants and tax-driven sales - Stock Titan
AGIOS (NASDAQ: AGIO) CCO reports new equity awards and tax-driven share sales - Stock Titan
Agios (AGIO) accounting officer sells shares to cover RSU tax withholding - Stock Titan
Agios (NASDAQ: AGIO) executive granted 14,000 RSUs and 52,000 options - Stock Titan
AGIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Agios Pharmaceuticals, Inc. Investigated by Shareholder Rights A - GuruFocus
Agios Pharmaceuticals Teases 2026 Catalysts as PYRUKYND Thalassemia Launch Gains Early Traction - MarketBeat
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer - AOL.com
AGIO (Nasdaq: AGIO) reports RSU vesting and Brian Goff sale disclosure - Stock Titan
AGIO (NASDAQ: AGIO) insider resale notice for 5,218 shares on 03/02/2026 - Stock Titan
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Insider sale notice: 5,035 AGIO shares tied to RSU vesting (NASDAQ: AGIO) - Stock Titan
Insider sells and RSUs vest at AGIO (NASDAQ: AGIO) — 2,868 RSUs listed - Stock Titan
AGIO: Mitapivat’s thalassemia launch accelerates, with pipeline and regulatory catalysts ahead - TradingView
Agios' Pyrukynd® (mitapivat) approved for adults with thalassemia in the United Arab Emirates - marketscreener.com
Agios Pharmaceuticals (AGIO) Gains UAE Approval for Pyrukynd - GuruFocus
Vanguard Group Inc. Sells 77,143 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - Bitget
Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - The Manila Times
UAE approves only treatment option for adults with thalassemia - Stock Titan
Agios Pharmaceuticals Q3 Loss Of US$103.4m Reinforces Bearish Profitability Narratives - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Passes Below Two Hundred Day Moving AverageShould You Sell? - MarketBeat
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash - AOL.com
Agios Pharmaceuticals, Inc. (AGIO) Stock Analysis: A 28.73% Upside Potential Amidst Strong Revenue Growth - DirectorsTalk Interviews
Understanding Momentum Shifts in (AGIO) - Stock Traders Daily
Agios Pharmaceuticals (AGIO) reports Q4 loss, beats revenue estimates - MSN
BOOTHBAY FUND MANAGEMENT, LLC's Agios Pharmaceuticals Inc(AGIO) Holding History - GuruFocus
Eagle Health Investments LP Sells 84,600 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Why Agios Pharmaceuticals Inc. stock is popular among millennialsTrade Volume Summary & High Yield Stock Recommendations - mfd.ru
Alpha Thalassemia Market to Reach US$ 1.9 Billion by 2031 | North - openPR.com
Agios’ 2025 Loss, AQVESME Launch, and New Shelf Offering Might Change The Case For Investing In Agios Pharmaceuticals (AGIO) - Sahm
HC Wainwright Issues Positive Estimate for AGIO Earnings - MarketBeat
Is Agios Pharmaceuticals Inc. stock overvalued by current metricsLayoff News & Smart Swing Trading Alerts - mfd.ru
RBC Capital Sticks to Their Hold Rating for Agios Pharma (AGIO) - The Globe and Mail
Agios Pharmaceuticals (AGIO) Is Up 5.4% After Mixed 2025 Results And AQVESME Launch Progress - Yahoo Finance
Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook - The Globe and Mail
Wall Street Zen Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat
Agios Pharmaceuticals Q4 2025 earnings preview - MSN
STATE STREET CORP Acquires Additional Shares in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - Finviz
Brokers Offer Predictions for AGIO FY2030 Earnings - MarketBeat
Decoding Agios Pharmaceuticals Inc (AGIO): A Strategic SWOT Insi - GuruFocus
Agios Q4 2025 slides: PYRUKYND revenue surges 86%, thalassemia launch underway - Investing.com Canada
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):